Table 2 Country-specific proportions of physicians who regularly tested for biomarkers in NMIBC patients
Biomarker | FR (n = 39) | DE (n = 39) | IT (n = 39) | ES (n = 49) | UK (n = 36) | US (n = 180) | JP (n = 91) | CN (n = 35) |
|---|---|---|---|---|---|---|---|---|
PD-1/PD-L1 | 41% | 56% | 38% | 18% | 39% | 27% | 7% | 54% |
CEA | 18% | 21% | 51% | 12% | 4% | 14% | 3% | 83% |
NMP22 | 5% | 13% | 3% | 4% | 3% | 24% | 21% | 20% |
Inflammatory markers† | 5% | 13% | 21% | 4% | 2% | 13% | 1% | 51% |
Tp53 | 10% | 13% | 15% | 4% | 1% | 18% | 2% | 31% |
FGFR3 | 13% | 15% | 5% | 6% | 5% | 1% | 2% | 9% |
BLCA-4 | 8% | 5% | 5% | 6% | 19% | 1% | 1% | 20% |
BLCA-1 | 10% | 8% | 5% | 4% | 5% | 12% | 3% | 23% |
Chromosome aneuploidy‡ | 3% | 3% | 3% | 0% | 1% | 16% | 1% | 20% |
HRAS | 0% | 5% | 5% | 4% | 1% | 9% | 3% | 11% |
Loss of 9p21 locus | 3% | 8% | 3% | 2% | 3% | 8% | 8% | 0% |
TERT promoter | 0% | 5% | 5% | 0% | 3% | 6% | 2% | 6% |
Mucins (LDQ10/M344) | 0% | 3% | 0% | 2% | 1% | 5% | 1% | 9% |
cFH | 3% | 3% | 0% | 0% | 3% | 3% | 3% | 3% |
Other | 3% | 0% | 3% | 2% | 3% | 1% | 0% | 0% |
None | 49% | 38% | 31% | 67% | 33% | 51% | 70% | 11% |